Señales en vivo de CTMX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 may 2024 @ 16:00):

Stats
Volumen de hoy	950 258
Volumen promedio	6.45M
Capitalización de mercado	132.46M
EPS	$0 ( 2024-05-14 )
Próxima fecha de ganancias	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	8.10
ATR14	$0.00400 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Young Matthew P.	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Su Zhen	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Mohindru Mani	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Meyers James R	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Jones Elaine V	Buy	38 000	Stock Option (Right to Buy)

INSIDER POWER
67.38
Last 98 transactions
Buy: 4 955 428 \| Sell: 1 092 240

Volumen Correlación

Largo: -0.54 (weak negative)

Corto: -0.47 (neutral)

Signal:(18.208) Neutral

CytomX Therapeutics Inc Correlación

10 Correlaciones Más Positivas
OZEM	1
LOGC	0.91
NALFX	0.894
BWIN	0.893
IIXIX	0.892
RGSVX	0.888
RGIVX	0.888
ANTUX	0.887
PGJZX	0.883
INFR	0.879

10 Correlaciones Más Negativas
PLTNU	-0.886
LDWY	-0.847
AAPD	-0.83
BRLSW	-0.828
CGON	-0.818
PXMD	-0.812

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CytomX Therapeutics Inc Correlación - Moneda/Commodity

0.78
( moderate )

0.76
( moderate )

0.00
( neutral )

-0.64
( weak negative )

CytomX Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$101.21M
Beneficio Bruto:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2023
Ingresos:	$101.21M
Beneficio Bruto:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2022
Ingresos:	$53.16M
Beneficio Bruto:	$47.31M (88.98 %)
EPS:	$-1.480

FY	2021
Ingresos:	$69.57M
Beneficio Bruto:	$69.57M (100.00 %)
EPS:	$-1.300

Financial Reports:

Symbol	Period	Year	Title
CTMX	Q1	2024	Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc.

CytomX Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.